CN109971755B - 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 - Google Patents
一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 Download PDFInfo
- Publication number
- CN109971755B CN109971755B CN201711449392.XA CN201711449392A CN109971755B CN 109971755 B CN109971755 B CN 109971755B CN 201711449392 A CN201711449392 A CN 201711449392A CN 109971755 B CN109971755 B CN 109971755B
- Authority
- CN
- China
- Prior art keywords
- sgrna
- cas9
- dnmt1
- gene
- cas9 plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091033409 CRISPR Proteins 0.000 title claims abstract description 136
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 title abstract description 36
- 238000010354 CRISPR gene editing Methods 0.000 title abstract 4
- 238000001415 gene therapy Methods 0.000 title description 12
- 238000005516 engineering process Methods 0.000 title description 10
- 238000010362 genome editing Methods 0.000 title description 10
- 229940079593 drug Drugs 0.000 title description 5
- 101100170936 Homo sapiens DNMT1 gene Proteins 0.000 claims abstract description 53
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 33
- 230000008685 targeting Effects 0.000 claims abstract description 25
- 239000013612 plasmid Substances 0.000 claims description 99
- 239000013600 plasmid vector Substances 0.000 claims description 52
- 108091034117 Oligonucleotide Proteins 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 39
- 238000003776 cleavage reaction Methods 0.000 claims description 19
- 230000007017 scission Effects 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 230000002441 reversible effect Effects 0.000 claims description 18
- 102000003960 Ligases Human genes 0.000 claims description 11
- 108090000364 Ligases Proteins 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 108700024394 Exon Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 238000001976 enzyme digestion Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 5
- 239000012876 carrier material Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001601 polyetherimide Polymers 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 54
- 101150007297 Dnmt1 gene Proteins 0.000 abstract description 31
- 210000004881 tumor cell Anatomy 0.000 abstract description 18
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 abstract description 17
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 abstract description 17
- 230000014509 gene expression Effects 0.000 abstract description 14
- 238000007069 methylation reaction Methods 0.000 abstract description 8
- 230000011987 methylation Effects 0.000 abstract description 7
- 238000010276 construction Methods 0.000 abstract description 4
- 239000013604 expression vector Substances 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 4
- 230000002779 inactivation Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 80
- 108090000623 proteins and genes Proteins 0.000 description 34
- 230000000694 effects Effects 0.000 description 30
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 21
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 18
- 102000057967 human DNMT1 Human genes 0.000 description 17
- 108010042407 Endonucleases Proteins 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 102100031780 Endonuclease Human genes 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000001638 lipofection Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 238000007480 sanger sequencing Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 108020005004 Guide RNA Proteins 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 101710163270 Nuclease Proteins 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 6
- 102000016397 Methyltransferase Human genes 0.000 description 6
- 108060004795 Methyltransferase Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091029523 CpG island Proteins 0.000 description 5
- 230000007067 DNA methylation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000012154 double-distilled water Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000037351 starvation Effects 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000011127 radiochemotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 2
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 2
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 description 2
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 2
- 229920000432 Polylactide-block-poly(ethylene glycol)-block-polylactide Polymers 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229920000762 poly(caprolactone)-poly(ethylene glycol)-poly(caprolactone) Polymers 0.000 description 2
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 description 2
- 229920001440 poly(ε-caprolactone)-block-poly(ethylene glycol) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 101710103504 CXXC-type zinc finger protein 1 Proteins 0.000 description 1
- 102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000004537 potential cytotoxicity Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 102100032270 tRNA (cytosine(38)-C(5))-methyltransferase Human genes 0.000 description 1
- 101710184308 tRNA (cytosine(38)-C(5))-methyltransferase Proteins 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711449392.XA CN109971755B (zh) | 2017-12-27 | 2017-12-27 | 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711449392.XA CN109971755B (zh) | 2017-12-27 | 2017-12-27 | 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109971755A CN109971755A (zh) | 2019-07-05 |
CN109971755B true CN109971755B (zh) | 2024-03-01 |
Family
ID=67072603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711449392.XA Active CN109971755B (zh) | 2017-12-27 | 2017-12-27 | 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109971755B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110974784B (zh) * | 2019-09-20 | 2021-01-12 | 中山大学 | 一种联合输送化疗药和基因编辑体系的多功能聚合物胶束及其制备方法和应用 |
CN112553195B (zh) * | 2020-11-05 | 2022-04-05 | 南方医科大学 | 一种用于CRISPR-Cas9定点突变编辑DNMT1基因的试剂及其应用 |
CN113201542B (zh) * | 2021-04-29 | 2023-05-16 | 天津医科大学 | 单链向导rna在制备治疗宫颈癌等靶向药物上的用途 |
CN115245574B (zh) * | 2022-06-09 | 2023-07-07 | 河南省人民医院 | 一种基于CRISPR-Cas9技术特异敲除人兔VEGFA的新型载基因药物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104971361A (zh) * | 2014-04-03 | 2015-10-14 | 四川大学 | 一种叶酸受体靶向的敲除dnmt1基因的药物组合物 |
CN105683379A (zh) * | 2013-06-17 | 2016-06-15 | 布罗德研究所有限公司 | 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化 |
-
2017
- 2017-12-27 CN CN201711449392.XA patent/CN109971755B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105683379A (zh) * | 2013-06-17 | 2016-06-15 | 布罗德研究所有限公司 | 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化 |
CN104971361A (zh) * | 2014-04-03 | 2015-10-14 | 四川大学 | 一种叶酸受体靶向的敲除dnmt1基因的药物组合物 |
Non-Patent Citations (1)
Title |
---|
利用dCas9-FokⅠ编辑大鼠Dnmt1基因;张旭等;《中国生物化学与分子生物学报》;第第32卷卷(第第7期期);第841-848页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109971755A (zh) | 2019-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109971755B (zh) | 一种基于CRISPR/Cas9基因编辑技术的靶向肿瘤的基因治疗药物及其用途 | |
US11591623B2 (en) | DNA methylation editing kit and DNA methylation editing method | |
US20210310022A1 (en) | Massively parallel combinatorial genetics for crispr | |
Han et al. | Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing | |
US20200385695A1 (en) | Compositions and methods for epigenome editing | |
US10519454B2 (en) | Genome editing using Campylobacter jejuni CRISPR/CAS system-derived RGEN | |
Bernstein et al. | TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts | |
JP2022069439A (ja) | 核酸塩基編集因子およびその使用 | |
CN111836894B (zh) | 用于使用CRISPR/Cpf1系统进行基因组编辑的组合物及其用途 | |
WO2017099494A1 (ko) | Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도 | |
WO2017208247A1 (en) | Assay for the removal of methyl-cytosine residues from dna | |
US20200172564A1 (en) | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | |
EP4227412A1 (en) | Engineered guide rna for increasing efficiency of crispr/cas12f1 (cas14a1) system, and use thereof | |
US20210355475A1 (en) | Optimized base editors enable efficient editing in cells, organoids and mice | |
Aquino-Jarquin | Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing | |
CN108285905B (zh) | 一种基于CRISPR-Cas13a的抑制真核细胞中基因表达水平的方法及其应用 | |
Mironova et al. | The systemic tumor response to RNase A treatment affects the expression of genes involved in maintaining cell malignancy | |
Wang et al. | CRISPR-Cas9 HDR system enhances AQP1 gene expression | |
Katayama et al. | Editing of DNA methylation using CRISPR/Cas9 and a ssDNA template in human cells | |
Burnett et al. | Examination of the cell cycle dependence of cytosine and adenine base editors | |
Choi et al. | Expanded targeting scope of LbCas12a variants allows editing of multiple oncogenic mutations | |
KR102679172B1 (ko) | 질환 세포-특이적인 miRNA에 의해 세포 생리 활성 조절 물질의 활성을 조절하는 복합체 및 이를 CRISPR/Cas 시스템에 적용한 질환 특이적 유전자 조작용 복합체 | |
WO2018217537A1 (en) | Selective insertion of suicide genes into cancer cells | |
US11965187B2 (en) | Targeted DNA demethylation method, fusion protein and application thereof preliminary class | |
Yi et al. | CRISPR-based m6A modification and its potential applications in telomerase regulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 610093 South Keyuan Road, Chengdu High-tech Zone, Chengdu, Sichuan Province, No. 88, 10 buildings, 2 floors, 203 Applicant after: Xinlitai (Chengdu) Biotechnology Co.,Ltd. Address before: 610093 South Keyuan Road, Chengdu High-tech Zone, Chengdu, Sichuan Province, No. 88, 10 buildings, 2 floors, 203 Applicant before: CHENGDU JINKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191105 Address after: 610041 Room 203, floor 2, building 10, No. 88, Keyuan South Road, hi tech Zone, Chengdu, Sichuan Province Applicant after: Xinlitai (Chengdu) Biotechnology Co.,Ltd. Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 610093 South Keyuan Road, Chengdu High-tech Zone, Chengdu, Sichuan Province, No. 88, 10 buildings, 2 floors, 203 Applicant before: Xinlitai (Chengdu) Biotechnology Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 610093 No. 1, floor 3, building 4, No. 1, Keyuan South Road, high tech Zone, Chengdu, Sichuan Applicant after: Xinlitai (Chengdu) Biotechnology Co.,Ltd. Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: No.203, 2 / F, building 10, No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Applicant before: Xinlitai (Chengdu) Biotechnology Co.,Ltd. Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |